Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Opioid capsule Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Pilot Study of Varenicline to Treat Opioid Dependence

NCT01436474
View directory record Official record
Conditions
Chronic Pain, Opioid Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 22, 2026, 4:38 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Zynrelef Versus Adductor Canal Block

NCT07216586
View directory record Official record
Conditions
Knee Osteoarthritis, Arthritis Knee
Interventions
ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

NCT05976646
View directory record Official record
Conditions
Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions
Placebo, Auvelity
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential Study of PF-00345439

NCT01986283
View directory record Official record
Conditions
Opioid Users
Interventions
Capsule, PF-00345439, oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Postop Pain After SSLF

NCT03123861
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Gabapentin, Placebo oral capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379
View directory record Official record
Conditions
Depression, Insulin Resistance, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Phase 3 Interventional

Adjunctive Cannabidiol for Recovery From Opioid Study

NCT06940674
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

NCT00597428
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
109
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tempe, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Managing Opioid Related Sleep Apnea With Acetazolamide

NCT06043830
View directory record Official record
Conditions
Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
Interventions
Acetazolamide, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Early Phase 1 Interventional Results available

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

NCT03958474
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Oxycodone
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Phase 2 Interventional

Axelopran for Advanced Cancer in Patients Receiving Opioids

NCT07354919
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreas Cancer, Prostate Cancer
Interventions
axelopran
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients

NCT00295308
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Clonidine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol in the Treatment of Opioid Use Disorder

NCT06206291
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Phase 2 Interventional

Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

NCT06981195
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Insomnia, Orexin Antagonist
Interventions
Placebo, Lemborexant 10 MG
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

NCT01418092
View directory record Official record
Conditions
OIC
Interventions
ALKS 37, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Anaheim, California • Orange, California • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Cebranopadol in Humans

NCT05256108
View directory record Official record
Conditions
Human Abuse Potential
Interventions
Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Phase 4 Interventional

Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO

NCT06952556
View directory record Official record
Conditions
Analgesia
Interventions
ACB, IPACK block
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 4:38 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine Sulfate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 22, 2026, 4:38 PM EDT